ORGANOGENESIS HOLDINGS INC. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $51.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $51.00K, a 93.16% decline from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $746.00K, a 492.06% increase from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $126.00K, a 32.26% decline from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $186.00K, a 71.99% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month as first filed |
|---|---|---|
| 2025-12-31 | $51.00K 10-K · filed 2026-02-26 | |
| 2024-12-31 | $746.00K 10-K · filed 2026-02-26 | |
| 2023-12-31 | $126.00K 10-K · filed 2026-02-26 | |
| 2022-12-31 | $186.00K 10-K · filed 2025-02-27 | |
| 2021-12-31 | $664.00K 10-K · filed 2024-02-29 | |
| 2020-12-31 | $606.00K 10-K · filed 2023-03-01 | |
| 2019-12-31 | $801.00K 10-K · filed 2022-03-01 | |
| 2018-12-31 | $357.00K 10-K · filed 2021-03-16 | |
| 2017-12-31 | $357.00K 10-K · filed 2020-03-09 | $408.00K 10-K · filed 2019-03-18 |
| 2016-12-31 | $408.00K 10-K · filed 2020-03-09 | $79.00K 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |